Is rapid initiation and titration of guideline-recommended medical therapy feasible and effective for optimizing treatment in newly diagnosed HFrEF?
Rapid initiation of guideline-recommended medical therapy for HFrEF is feasible in real-world practice, but proactive ongoing dose titration remains necessary for optimal care.
The TITRATE-HF study demonstrates that rapid initiation of GRMT for HFrEF is feasible in real-world clinical practice. Nonetheless, our results highlight the urgency for a proactive approach and ongoing dose titration of pharmacological therapy beyond the initial first months to fully optimize treatment.
Malgie et al. (Sat,) studied this question.